Angelman Syndrome Biomarker & Outcome Measure Consortium (ABOM): Understanding What Matters to Patients with a Heterogenous Neurodevelopmental Disorder
Time: 4:30 pm
day: Day One
Details:
• NHS, Disease concept models and focus domains on what is important to patients and caregivers: Staying pre-competitive
